Dianthus Therapeutics, Inc. /DE/ Increase (Decrease) in Due from Related Parties
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Increase (Decrease) in Due from Related Parties of -$807.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueFromRelatedParties · last filed 2025-05-12
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in due from related parties for the quarter ending 2025-03-31 was -$807.00K, a 672.34% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in due from related parties for the quarter ending 2024-12-31 was -$583.00K, a 1040.32% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in due from related parties for the quarter ending 2024-09-30 was $550.00K.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in due from related parties for the quarter ending 2024-06-30 was $405.00K.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in due from related parties for fiscal 2024 was $513.00K.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in due from related parties for fiscal 2023 was -$4.41M, a 204.14% decline from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ increase (decrease) in due from related parties for fiscal 2022 was $4.23M.
| Period end | Increase (Decrease) in Due from Related Parties 3 month | Increase (Decrease) in Due from Related Parties 6 month | Increase (Decrease) in Due from Related Parties 9 month | Increase (Decrease) in Due from Related Parties 12 month |
|---|---|---|---|---|
| 2025-03-31 | -$807.00K 10-Q · filed 2025-05-12 | -$1.39M derived: sum of 2 quarters · filed 2025-05-12 | -$840.00K derived: sum of 3 quarters · filed 2025-05-12 | -$435.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | -$583.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$33.00K derived: sum of 2 quarters · filed 2025-03-11 | $372.00K derived: sum of 3 quarters · filed 2025-03-11 | $513.00K 10-K · filed 2025-03-11 |
| 2024-09-30 | $550.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $955.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.10M 10-Q · filed 2024-11-07 | $1.16M derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-06-30 | $405.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $546.00K 10-Q · filed 2024-08-08 | $608.00K derived: sum of 3 quarters · filed 2025-05-12 | $478.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-03-31 | $141.00K 10-Q · filed 2025-05-12 | $203.00K derived: sum of 2 quarters · filed 2025-05-12 | $73.00K derived: sum of 3 quarters · filed 2025-05-12 | -$3.48M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$68.00K derived: sum of 2 quarters · filed 2025-03-11 | -$3.62M derived: sum of 3 quarters · filed 2025-03-11 | -$4.41M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$130.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$3.68M derived: sum of 2 quarters · filed 2024-11-07 | -$4.47M 10-Q · filed 2024-11-07 | -$1.32M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$3.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$4.34M 10-Q · filed 2024-08-08 | -$1.19M derived: sum of 3 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$789.00K 10-Q · filed 2024-05-09 | $2.36M derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $4.23M 10-K · filed 2024-03-21 | ||
| 2022-09-30 | $1.08M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $469.00K 8-K · filed 2023-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |